ISRAEL GENERIC BIOCHIP TECHNOLOGY CONSORTIUM
The Israeli Bio-Chip consortium has been organized and financed by the MAGNET Program of the Israel Innovation Authority. The consortium consists of 7 industrial companies (Tower SC, CEVA, PLSense QuLab medical, Cardiokol , SensoMedical, Israel Aerospace Industry) and 12 research groups from 4 different academic institutes (Technion, Bar-Ilan, Ben-Gurion, TAU).
The main goal of the consortium is to develop and bring to market innovative-generic Bio-chips technologies which will be available for the emerging Israeli Bio-Medical sector and will bridge the current existing gap in the industry.
The consortium will develop various biosensors and supportive technologies with emphasis on innovative low power circuits, chip manufacturing technologies, microfluidics, optical applications, and AI capabilities needed for bio-chip based systems. The technologies will be demonstrated on metabolic sensing, innovative heart-arrhythmia detection, analog bio-sensors, EEG, synthetic biology and more. The project started in November 2021 and is planned for 3 years in 2 phases of 18 month.